Antiangiogenic Drugs and Current Strategies for the Treatment of Lung Cancer

Seminars in Oncology

Volumn 31, Issue 1 SUPPL. 1, 2004, Pages 54-60

  Kerbel, Robert S ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AE 941; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; COMBRETASTATIN; FLUOROURACIL; FOLINIC ACID; INTEGRIN; IRINOTECAN; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY LM 609; N ACETYLCOLCHINOL PHOSPHATE; SEMAXANIB; THALIDOMIDE; THROMBOSPONDIN 1; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VASCULAR TARGETING AGENT; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2; VATALANIB; ZK 22284;

ANGIOGENESIS; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLON CANCER; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MESOTHELIOMA; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

EID: 1242318823     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.12.015     Document Type: Article

References (53)

1. Hurwitz H, Fehrenbacher L, Cartwright T, et al: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 22, 2003 (abstr 3646)
2. Miller KD, Rugo HS, Cobleigh MA, et al: Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin versus capecitabine alone) in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 76:S37, 2002 (abstr 36) (suppl 1)
3. Stadler W, Wilding G: Angiogenesis inhibitors in genitourinary cancers. Crit Rev Oncol Hematol 46:41-47, 2003 (suppl 1)
4. Shepherd FA, Sridhar SS: Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer 41:S63-S72, 2003 (suppl 1)
5. National Cancer Institute. Clinical trials database. Available at: http://cancer.gov/clinicaltrials. (accessed August 1, 2003)
6. Kerbel RS: Clinical trials of antiangiogenic drugs: Opportunities, problems, and assessment of initial results. J Clin Oncol 19:45S-51S, 2001 (suppl)
7. Rustin GJ, Galbraith SM, Anderson H, et al: Phase I clinical trial of weekly combretastatin A4 phosphate: Clinical and pharmacokinetic results. J Clin Oncol 21:2815-2822, 2003
8. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795-803, 2002
9. Wood JM, Bold G, Buchdunger E, et al: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189, 2000
10. Boyer SJ: Small molecule inhibitors of KDR (VEGFR-2) kinase: An overview of structure activity relationships. Curr Top Med Chem 2:973-1000, 2002
11. Masood R, Kundra A, Zhu S, et al: Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 104:603-610, 2003
12. Posey JA, Ng TC, Yang B, et al: A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 9:1323-1332, 2003
13. Falardeau P, Champagne P, Poyet P, et al: Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 28:620-625, 2001
14. Pavlakovic H, Havers W, Schweigerer L: Multiple angiogenesis stimulators in a single malignancy: Implications for anti-angiogenic tumour therapy. Angiogenesis 4:259-262, 2001
15. Relf M, LeJeune S, Scott PA, et al: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963-969, 1997
16. Yang J, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
17. Brekken RA, Thorpe PE: Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res 21:4221-4229, 2001
18. Koukourakis MI, Giatromanolaki A, Thorpe PE, et al: Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 60:3088-3095, 2000
19. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787-2799, 2003
20. Cristofanilli M, Charnsangavej C, Hortobagyi GN: Angiogenesis modulation in cancer research: Novel clinical approaches. Nat Rev Drug Discov 1:415-426, 2002
21. Rothenberg ML, Carbone DP, Johnson DH: Improving the evaluation of new cancer treatments: Challenges and opportunities. Nat Rev Cancer 3:303-309, 2003
22. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
23. Davis DW, McConkey DJ, Abbruzzese JL, et al: Surrogate markers in antiangiogenesis clinical trials. Br J Cancer 89:8-14, 2003
24. Pegram MD, Finn RS, Arzoo K, et al: The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15:537-547, 1997
25. Hanahan D, Bergers G, Bergsland E: Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045-1047, 2000
26. Klement G, Baruchel S, Rak J, et al: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-R24, 2000
27. Browder T, Butterfield CE, Kraling BM, et al: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886, 2000
28. Herbst RS, Hidalgo M, Pierson AS, et al: Angiogenesis inhibitors in clinical development for lung cancer. Semin Oncol 29:66-77, 2002
29. Delmotte P, Martin B, Paesmans M, et al: VEGF and survival of patients with lung cancer: A systematic literature review and meta-analysis. Rev Mal Respir 19:577-584, 2002
30. Meert AP, Paesmans M, Martin B, et al: The role of microvessel density on the survival of patients with lung cancer: A systematic review of the literature with meta-analysis. Br J Cancer 87:694-701, 2002
31. Masuya D, Huang C, Liu D, et al: The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer 92:2628-2638, 2001
32. Chen JJ, Yao PL, Yuan A, et al: Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: Its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 9:729-737, 2003
33. Ruotsalainen T, Joensuu H, Mattson K, et al: High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. Cancer Epidemiol Biomarkers Prev 11:1492-1495, 2002
34. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, et al: Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 82:1427-1432, 2000
35. Tanaka F, Ishikawa S, Yanagihara K, et al: Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 62:7124-7129, 2002
36. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003
37. Petit AM, Rak J, Hung MC, et al: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523-1530, 1997
38. Abrams TJ, Lee LB, Murray LJ, et al: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in pre-clinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478, 2003
39. Ohta Y, Shridhar V, Bright RK, et al: VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81:54-61, 1999
40. Strizzi L, Catalano A, Vianale G, et al: Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193:468-475, 2001
41. Pezzella F, Pastorino U, Tagliabue E, et al: Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 151:1417-1423, 1997
42. Passalidou E, Trivella M, Singh N, et al: Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer 86:244-249, 2002
43. Breast Cancer Progression Working Party: Evidence for novel non-angiogenic pathway in breast-cancer metastasis. Lancet 355:1787-1788, 2000
44. Li L, Rojiani A, Siemann DW: Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy. Int J Radiat Oncol Biol Phys 42:899-903, 1998
45. Goto H, Yano S, Zhang H, et al: Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res 62:3711-3715, 2002
46. Anderson HL, Yap JT, Miller MP, et al: Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin a4 phosphate. J Clin Oncol 21:2823-2830, 2003
47. Iyer S, Chaplin DJ, Rosenthal DS, et al: Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 58:4510-4514, 1998
48. Kanthou C, Tozer GM: The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99:2060-2069, 2002
49. Nelkin BD, Ball DW: Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep 8:157-160, 2001
50. Altorki NK, Keresztes RS, Port JL, et al: Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21:2645-2650, 2003
51. Simon GR, Bunn PA Jr: Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): Recent developments. Cancer Invest 21:87-104, 2003
52. Hirsh V, Whittom R, Ofiara L, et al: Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC): A dose-optimizing phase II trial. Cancer 97:2242-2247, 2003
53. Taraboletti G, Micheletti G, Rieppi M, et al: Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin Cancer Res 8:1182-1188, 2002